智通财经网·2026-01-30 09:29Core Viewpoint - The company, Hepalink (09989), expects a significant decline in net profit attributable to shareholders for the year ending December 31, 2025, projecting between RMB 284 million and RMB 377 million, representing a year-on-year decrease of 41.71% to 56.09% [1] Group 1: Financial Performance - The company reported notable growth in the global heparin product market, with steady sales performance across regions and an increase in market share, particularly with a double-digit growth in enoxaparin sales [1] - The decline in net profit is primarily attributed to a high base from the previous year, which included a one-time investment gain exceeding RMB 350 million [1] - The company's net profit, excluding non-recurring items, showed growth compared to the previous year, driven by steady increases in main business revenue and profit [1] Group 2: Operational Efficiency - The company has been enhancing financial management and optimizing resource allocation to improve operational efficiency and drive continuous improvement in profitability [1] - Despite the anticipated impact from the joint venture's underperformance in R&D, the company still achieved steady growth in net profit after excluding non-recurring items, demonstrating resilience and sustained growth capability in its core business [1]